Have a feature idea you'd love to see implemented?
Let us know!
TXG 10x Genomics Inc
Price (delayed)
$13.29
Market cap
$1.61B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$1.3B
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin
Highlights
The company's net income rose by 24% QoQ and by 18% YoY
TXG's EPS is up by 24% since the previous quarter and by 20% year-on-year
The company's gross margin fell by 4.7% YoY but it rose by 2.9% QoQ
The company's quick ratio fell by 10% YoY and by 6% QoQ
TXG's equity is down by 3% year-on-year
Key stats
What are the main financial stats of TXG
Market
Valuations
Earnings
Shares outstanding
121.05M
Market cap
$1.61B
Enterprise value
$1.3B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
2.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.06
Revenue
$629.74M
EBIT
-$175.91M
EBITDA
-$131.06M
Free cash flow
$26.04M
Per share
Balance sheet
Liquidity
EPS
-$1.53
Free cash flow per share
$0.22
Book value per share
$6
Revenue per share
$5.22
TBVPS
$7.6
Total assets
$937.79M
Total liabilities
$214.99M
Debt
$85.88M
Equity
$722.8M
Working capital
$472.66M
Debt to equity
0.12
Current ratio
4.9
Quick ratio
3.97
Net debt/EBITDA
2.38
Margins
Efficiency
Dividend
EBITDA margin
-20.8%
Gross margin
66.6%
Net margin
-29%
Operating margin
-31.7%
Return on assets
-19.4%
Return on equity
-25.1%
Return on invested capital
-33.9%
Return on capital employed
-21.5%
Return on sales
-27.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TXG stock price
How has the 10x Genomics stock price performed over time
Intraday
-0.23%
1 week
-5.88%
1 month
-13.53%
1 year
-68.96%
YTD
-76.25%
QTD
-41.14%
Financial performance
How have 10x Genomics's revenue and profit performed over time
Revenue
$629.74M
Gross profit
$419.31M
Operating income
-$199.91M
Net income
-$182.55M
Gross margin
66.6%
Net margin
-29%
The company's net income rose by 24% QoQ and by 18% YoY
10x Genomics's net margin has increased by 24% QoQ and by 23% YoY
TXG's operating income is up by 21% since the previous quarter and by 14% year-on-year
10x Genomics's operating margin has increased by 21% QoQ and by 20% YoY
Growth
What is 10x Genomics's growth rate over time
Valuation
What is 10x Genomics stock price valuation
P/E
N/A
P/B
2.22
P/S
2.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.06
TXG's EPS is up by 24% since the previous quarter and by 20% year-on-year
The P/B is 83% below the 5-year quarterly average of 12.8 and 60% below the last 4 quarters average of 5.5
TXG's equity is down by 3% year-on-year
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 22.3 and 60% less than its last 4 quarters average of 6.4
10x Genomics's revenue has increased by 7% YoY
Efficiency
How efficient is 10x Genomics business performance
TXG's ROS is up by 25% year-on-year and by 24% since the previous quarter
TXG's ROA is up by 24% from the previous quarter and by 13% YoY
The ROE has grown by 23% from the previous quarter and by 12% YoY
The return on invested capital is up by 20% since the previous quarter
Dividends
What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TXG.
Financial health
How did 10x Genomics financials performed over time
The company's quick ratio fell by 10% YoY and by 6% QoQ
The current ratio has contracted by 9% YoY and by 6% from the previous quarter
10x Genomics's debt is 88% lower than its equity
10x Genomics's debt has decreased by 13% YoY and by 4% QoQ
10x Genomics's debt to equity has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.